Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

We report on a novel series of aryl sulfonamides that act as nanomolar potent, isoform-selective inhibitors of the human sodium channel hNaV1.7. The optimization of these inhibitors is described. We aimed to improve potency against hNaV1.7 while minimizing off-target safety concerns and generated compound 3. This agent displayed significant analgesic effects in rodent models of acute and inflammatory pain and demonstrated that binding to the voltage sensor domain 4 site of NaV1.7 leads to an analgesic effect in vivo. Our findings corroborate the importance of hNaV1.7 as a drug target for the treatment of pain.

[1]  Matthew S. Johnson,et al.  A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat , 2007, Proceedings of the National Academy of Sciences.

[2]  A. Dickenson,et al.  Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons , 2012, Nature Communications.

[3]  W. Catterall,et al.  Voltage-gated ion channels and gating modifier toxins. , 2007, Toxicon : official journal of the International Society on Toxinology.

[4]  John N. Wood,et al.  Neurological perspectives on voltage-gated sodium channels , 2012, Brain : a journal of neurology.

[5]  Tom H. H. Hsieh,et al.  Tetracyclic spirooxindole blockers of hNaV1.7: activity in vitro and in CFA-induced inflammatory pain model , 2013, Medicinal Chemistry Research.

[6]  S. England,et al.  Isoform-selective voltage-gated Na(+) channel modulators as next-generation analgesics. , 2010, Future medicinal chemistry.

[7]  T. Yaksh,et al.  An automated flinch detecting system for use in the formalin nociceptive bioassay. , 2001, Journal of applied physiology.

[8]  M. Hayden,et al.  Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker , 2012, PAIN.

[9]  C. Cohen,et al.  Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010. , 2014, Pharmaceutical patent analyst.

[10]  Seok-Yong Lee,et al.  RETRACTED: A Monoclonal Antibody that Targets a NaV1.7 Channel Voltage Sensor for Pain and Itch Relief , 2014, Cell.

[11]  G. Forlani,et al.  Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  N. Damann,et al.  Advances in Targeting Voltage‐Gated Sodium Channels with Small Molecules , 2012, ChemMedChem.

[13]  M. D. de Groot,et al.  Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels , 2013, Proceedings of the National Academy of Sciences.

[14]  Sharan K Bagal,et al.  Recent progress in sodium channel modulators for pain. , 2014, Bioorganic & medicinal chemistry letters.

[15]  P. Grafe,et al.  Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current , 2012, Proceedings of the National Academy of Sciences.

[16]  Manuel de Lera Ruiz,et al.  Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. , 2015, Journal of medicinal chemistry.

[17]  S. Dib-Hajj,et al.  The NaV1.7 sodium channel: from molecule to man , 2012, Nature Reviews Neuroscience.

[18]  Jianmin Fu,et al.  Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain. , 2011, Bioorganic & medicinal chemistry letters.

[19]  Jun Li,et al.  Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist , 2015, Science.

[20]  J. Wood,et al.  Pain without Nociceptors? Nav1.7-Independent Pain Mechanisms , 2014, Cell reports.